<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml">
  <head>
    
<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
<title>Akers Biosciences' (AKER) Management Discussion on Q2 2015 Results - Earnings Call Transcript | Seeking Alpha</title>
<meta name="application-name" content="Seeking Alpha - Read, Decide, Invest."/>
<meta name='viewport' content='width=1300'>


<meta http-equiv="x-dns-prefetch-control" content="on">
<link rel="dns-prefetch" href="//staticseekingalpha.a.ssl.fastly.net">
<link rel="dns-prefetch" href="//staticseekingalpha1.a.ssl.fastly.net">
<link rel="dns-prefetch" href="//staticseekingalpha2.a.ssl.fastly.net">
<link rel="dns-prefetch" href="//staticseekingalpha3.a.ssl.fastly.net">

<link href="//staticseekingalpha2.a.ssl.fastly.net/assets/favicon-46530755d46bb8a9005e583874cd8e5e.ico" rel="shortcut icon" type="image/ico">
<link rel="icon" type="image/png" href="//staticseekingalpha1.a.ssl.fastly.net/assets/favicon-16x16-09faeeb3fe8e97eb4b92edb8f904d792.png" sizes="16x16">
<link rel="icon" type="image/png" href="//staticseekingalpha2.a.ssl.fastly.net/assets/favicon-32x32-2208d73dfe9595e55f907c9ded5cc353.png" sizes="32x32">
<link rel="icon" type="image/png" href="//staticseekingalpha.a.ssl.fastly.net/assets/favicon-96x96-4f389eca45e750f5651a690469eb0af5.png" sizes="96x96">
<link rel="icon" type="image/png" href="//staticseekingalpha3.a.ssl.fastly.net/assets/favicon-192x192-6c9d478d320e913dc8644e519b4c1766.png" sizes="192x192">

<meta name="description" content="Akers Biosciences Inc. (NASDAQ:AKER) Q2 2015 Results Earnings Conference August 18, 2015, 09:00 AM ET Executives Ben Simons - Investor Relations Ray Akers - Co-" /><meta name="keywords" content="NASDAQ:AKER" /><meta name="news_keywords" content="AKER, Akers Biosciences Inc., Healthcare, Transcripts, United States, Medical Appliances & Equipment" /><meta name="syndication-source" content="http://seekingalpha.com/article/3448766-akers-biosciences-aker-management-discussion-on-q2-2015-results-earnings-call-transcript"><link rel="canonical" href="http://seekingalpha.com/article/3448766-akers-biosciences-aker-management-discussion-on-q2-2015-results-earnings-call-transcript" />


<script type="text/javascript">window.NREUM||(NREUM={});NREUM.info={"beacon":"bam.nr-data.net","errorBeacon":"bam.nr-data.net","licenseKey":"c0370b1d43","applicationID":"334927,334964","transactionName":"cldeEUAJWgldEBsASkVRUwlXFRkWUA1D","queueTime":1,"applicationTime":76,"agent":"js-agent.newrelic.com/nr-686.min.js"}</script>
<script type="text/javascript">window.NREUM||(NREUM={}),__nr_require=function(e,n,t){function r(t){if(!n[t]){var o=n[t]={exports:{}};e[t][0].call(o.exports,function(n){var o=e[t][1][n];return r(o?o:n)},o,o.exports)}return n[t].exports}if("function"==typeof __nr_require)return __nr_require;for(var o=0;o<t.length;o++)r(t[o]);return r}({QJf3ax:[function(e,n){function t(e){function n(n,t,a){e&&e(n,t,a),a||(a={});for(var u=c(n),f=u.length,s=i(a,o,r),p=0;f>p;p++)u[p].apply(s,t);return s}function a(e,n){f[e]=c(e).concat(n)}function c(e){return f[e]||[]}function u(){return t(n)}var f={};return{on:a,emit:n,create:u,listeners:c,_events:f}}function r(){return{}}var o="nr@context",i=e("gos");n.exports=t()},{gos:"7eSDFh"}],ee:[function(e,n){n.exports=e("QJf3ax")},{}],3:[function(e,n){function t(e){return function(){r(e,[(new Date).getTime()].concat(i(arguments)))}}var r=e("handle"),o=e(1),i=e(2);"undefined"==typeof window.newrelic&&(newrelic=window.NREUM);var a=["setPageViewName","addPageAction","setCustomAttribute","finished","addToTrace","inlineHit","noticeError"];o(a,function(e,n){window.NREUM[n]=t("api-"+n)}),n.exports=window.NREUM},{1:12,2:13,handle:"D5DuLP"}],gos:[function(e,n){n.exports=e("7eSDFh")},{}],"7eSDFh":[function(e,n){function t(e,n,t){if(r.call(e,n))return e[n];var o=t();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(e,n,{value:o,writable:!0,enumerable:!1}),o}catch(i){}return e[n]=o,o}var r=Object.prototype.hasOwnProperty;n.exports=t},{}],D5DuLP:[function(e,n){function t(e,n,t){return r.listeners(e).length?r.emit(e,n,t):void(r.q&&(r.q[e]||(r.q[e]=[]),r.q[e].push(n)))}var r=e("ee").create();n.exports=t,t.ee=r,r.q={}},{ee:"QJf3ax"}],handle:[function(e,n){n.exports=e("D5DuLP")},{}],XL7HBI:[function(e,n){function t(e){var n=typeof e;return!e||"object"!==n&&"function"!==n?-1:e===window?0:i(e,o,function(){return r++})}var r=1,o="nr@id",i=e("gos");n.exports=t},{gos:"7eSDFh"}],id:[function(e,n){n.exports=e("XL7HBI")},{}],G9z0Bl:[function(e,n){function t(){var e=d.info=NREUM.info,n=f.getElementsByTagName("script")[0];if(e&&e.licenseKey&&e.applicationID&&n){c(p,function(n,t){n in e||(e[n]=t)});var t="https"===s.split(":")[0]||e.sslForHttp;d.proto=t?"https://":"http://",a("mark",["onload",i()]);var r=f.createElement("script");r.src=d.proto+e.agent,n.parentNode.insertBefore(r,n)}}function r(){"complete"===f.readyState&&o()}function o(){a("mark",["domContent",i()])}function i(){return(new Date).getTime()}var a=e("handle"),c=e(1),u=window,f=u.document;e(2);var s=(""+location).split("?")[0],p={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net",agent:"js-agent.newrelic.com/nr-686.min.js"},d=n.exports={offset:i(),origin:s,features:{}};f.addEventListener?(f.addEventListener("DOMContentLoaded",o,!1),u.addEventListener("load",t,!1)):(f.attachEvent("onreadystatechange",r),u.attachEvent("onload",t)),a("mark",["firstbyte",i()])},{1:12,2:3,handle:"D5DuLP"}],loader:[function(e,n){n.exports=e("G9z0Bl")},{}],12:[function(e,n){function t(e,n){var t=[],o="",i=0;for(o in e)r.call(e,o)&&(t[i]=n(o,e[o]),i+=1);return t}var r=Object.prototype.hasOwnProperty;n.exports=t},{}],13:[function(e,n){function t(e,n,t){n||(n=0),"undefined"==typeof t&&(t=e?e.length:0);for(var r=-1,o=t-n||0,i=Array(0>o?0:o);++r<o;)i[r]=e[n+r];return i}n.exports=t},{}]},{},["G9z0Bl"]);</script>
<meta name="apple-mobile-web-app-capable" content="yes">
<meta name="apple-mobile-web-app-status-bar-style" content="black">
<link rel="apple-touch-icon" sizes="57x57" href="//staticseekingalpha3.a.ssl.fastly.net/assets/apple/apple-touch-icon-57x57-a93a575c6dc6cfd0a797599e5a4aca43.png">
<link rel="apple-touch-icon" sizes="72x72" href="//staticseekingalpha2.a.ssl.fastly.net/assets/apple/apple-touch-icon-72x72-83db8db36f683647f2ea4912ef925672.png">
<link rel="apple-touch-icon" sizes="114x114" href="//staticseekingalpha3.a.ssl.fastly.net/assets/apple/apple-touch-icon-114x114-2dc61d132d5605efaec1fbc0f9928d87.png">
<link rel="apple-touch-icon" sizes="144x144" href="//staticseekingalpha.a.ssl.fastly.net/assets/apple/apple-touch-icon-144x144-71696df71f280a287129fa94bed7c653.png">
<link rel="apple-touch-icon" sizes="180x180" href="//staticseekingalpha.a.ssl.fastly.net/assets/apple/apple-touch-icon-180x180-d834ebf09d4ac710eba277348673886f.png">

<meta name="msapplication-config" content="//staticseekingalpha1.a.ssl.fastly.net/assets/ms/browserconfig-3991a8a2de372679027124c341359bf3.xml">
<meta name="msapplication-TileColor" content="#ff7200">
<meta name="msapplication-TileImage" content="//staticseekingalpha3.a.ssl.fastly.net/assets/ms/mstile-144x144-5156f086afb634519136fbe3bb36f435.png">
<link rel="icon" sizes="any" mask href="//staticseekingalpha2.a.ssl.fastly.net/assets/favicon-0e616d30d1102b37d7e06f1a53822ca1.svg">
<meta name="theme-color" content="#ffffff">

<meta property="og:locale" content="en_US">
<meta property="og:site_name" content="Seeking Alpha">
<meta property="og:title" content="Akers Biosciences' (AKER) Management Discussion on Q2 2015 Results - Earnings Call Transcript">
<meta property="og:url" content="http://seekingalpha.com/earnings_center/all/article/3448766">
<meta property="og:image" content="//staticseekingalpha3.a.ssl.fastly.net/assets/social-50f1e86b5c7a0fda6a96bf2280e5360d.png">
<meta property="og:description" content="Akers Biosciences Inc. (NASDAQ:AKER) Q2 2015 Results Earnings Conference August 18, 2015, 09:00 AM ET Executives Ben Simons - Investor Relations Ray Akers - Co-Founder and Executive Chairman Gary Rauch – Vice President of Fin">

<meta name="twitter:card" content="summary">
<meta name="twitter:site" content="@SeekingAlpha">
<meta name="twitter:title" content="Akers Biosciences' (AKER) Management Discussion on Q2 2015 Results - Earnings Call Transcript">
<meta name="twitter:image" content="//staticseekingalpha1.a.ssl.fastly.net/images/users_profile/000/101/639/big_pic.png?1361390405">
<meta name="twitter:description" content="Akers Biosciences Inc. (NASDAQ:AKER) Q2 2015 Results Earnings Conference August 18, 2015, 09:00 AM ET Executives Ben Simons - Investor Relations Ray Akers - Co-Founder and Executive Chairman Gary Rauc">

<meta property="fb:admins" content="100006791796236" />

<link href="//staticseekingalpha1.a.ssl.fastly.net/stylesheets/packaged/performance_layout_packaged.css?h=1yw2rdg.css" media="screen" rel="stylesheet" type="text/css" /><link href="//staticseekingalpha.a.ssl.fastly.net/stylesheets/packaged/performance_layout_b_packaged.css?h=1b42syq.css" media="screen" rel="stylesheet" type="text/css" /><link href="//staticseekingalpha3.a.ssl.fastly.net/stylesheets/packaged/article_packaged.css?h=6wcxhb.css" media="screen" rel="stylesheet" type="text/css" />
<!-- BEGIN Krux Control Tag for "seekingalpha.com" -->
<!-- Source: /snippet/controltag?confid=Jubkx3MY&site=seekingalpha.com&edit=1 -->
<script class="kxct" data-id="Jubkx3MY" data-timing="async" data-version="1.9" type="text/javascript">
    window.Krux || ((Krux = function () {
        Krux.q.push(arguments)
    }).q = []);
    (function () {
        var k = document.createElement('script');
        k.type = 'text/javascript';
        k.async = true;
        var m, src = (m = location.href.match(/\bkxsrc=([^&]+)/)) && decodeURIComponent(m[1]);
        k.src = /^https?:\/\/([a-z0-9_\-\.]+\.)?krxd\.net(:\d{1,5})?\//i.test(src) ? src : src === "disable" ? "" :
        (location.protocol === "https:" ? "https:" : "http:") + "//cdn.krxd.net/controltag?confid=Jubkx3MY"
        ;
        var s = document.getElementsByTagName('script')[0];
        s.parentNode.insertBefore(k, s);
    }());
    (function(){
    function retrieve(n){
        var m, k='kx'+n;
        if(window.localStorage){
            return window.localStorage[k] || "";
        }else if(navigator.cookieEnabled){
            m = document.cookie.match(k+'=([^;]*)');
            return (m && unescape(m[1])) || "";
        }else{
            return '';
        }
    }
    Krux.user = retrieve('user');
    Krux.segments = retrieve('segs') && retrieve('segs').split(',') || [];
    })();

</script>
<!-- END Krux Controltag -->





<script type="text/javascript">
  window.PAGE_START_TS = new Date().getTime(); //will be put in mone
  window.primaryMarketCap = 19447484;
  window.primaryTickerSlug = "aker";
  var users_on_site='4,567,213';
  var user_cookie={};

  function readCookie(name) {
    var cookie = document.cookie.match(new RegExp('(^|;)\\s*' + escape(name) + '=([^;\\s]*)'));
    return (cookie ? unescape(cookie[2]) : null);
  }

  function addToCookie(key,value) {
    var arr=user_cookie[key].split(',');
    arr.push(value);

    user_cookie[key]=arr.join(',');
  }
  if (readCookie('user_cookie_key')) {
    document.write('<scr'+'ipt src="//staticseekingalpha.a.ssl.fastly.net/account/cookie/'+readCookie('user_cookie_key')+'"></scri'+'pt>');
  } else if (readCookie('user_id')) {
    document.write('<scr'+'ipt src="/account/no_cookie_key"></scri'+'pt>');
  }

  var isThisMyFirstPV = false;
  var _comscore = _comscore || [];
  _comscore.push({ c1: "2", c2: "8500672" });
    (function() {
      var s = document.createElement("script"), el = document.getElementsByTagName("script")[0]; s.async = true;
      s.src = (document.location.protocol == "https:" ? "https://sb" : "http://b") + ".scorecardresearch.com/beacon.js";
      el.parentNode.insertBefore(s, el);
    })();

  var is_pro = false;


  var ASSET_HOSTS = ["//staticseekingalpha.a.ssl.fastly.net","//staticseekingalpha1.a.ssl.fastly.net","//staticseekingalpha2.a.ssl.fastly.net","//staticseekingalpha3.a.ssl.fastly.net"];
</script>
<script crossorigin="use-credentials" src="//staticseekingalpha2.a.ssl.fastly.net/javascripts/packaged/common_packaged.js?h=1rju14v.js" type="text/javascript"></script>
<script crossorigin="use-credentials" src="//staticseekingalpha1.a.ssl.fastly.net/javascripts/packaged/common2_packaged.js?h=lq8ds6.js" type="text/javascript"></script>
<script crossorigin="use-credentials" src="//staticseekingalpha1.a.ssl.fastly.net/javascripts/packaged/coffee_packaged.js?h=1a31cfu.js" type="text/javascript"></script><script crossorigin="use-credentials" src="//staticseekingalpha.a.ssl.fastly.net/javascripts/packaged/common_article_packaged.js?h=jobbp6.js" type="text/javascript"></script>  <script src="//staticseekingalpha.a.ssl.fastly.net/memcached2/symbol_rt_data"></script>

      <script>
      if (!SA.Utils.SASource.didInitialWithEmailInUrl()) {
        document.write('<scr'+'ipt src="//partner.googleadservices.com/gampad/google_service.js" type="text/javascript"></scri'+'pt>');
      }
    </script>
<script>
  var adata = SA.Data.Cache.get('campaign_content');
</script>

        <script id="liftigniter-metadata" type="application/json">
      {
        "author_name": "SA Transcripts",
        "author_image": "//staticseekingalpha1.a.ssl.fastly.net/images/users_profile/000/101/639/big_pic.png?1361390405",
        "id": "3448766",
        "primary_ticker": "aker",
        "published_time": "2015-08-18 12:55:09 -0400",
        "publish_time": "2015-08-18 12:55:09 -0400"
      }
    </script>
    <script>
  (function(w,d,s,p,v,e,r) {w['$petametrics_var']=v;w[v]=w[v]||function(){(w[v].q=w[v].q||[]).push(arguments)};w[v].l=1*new Date();e=d.createElement(s),r=d.getElementsByTagName(s)[0];e.async=1;e.src=p;r.parentNode.insertBefore(e,r)})(window,document,'script','//cdn.petametrics.com/p.js','$p');
  $p("init", "k2lfmn21cq6srufb");
  $p("send", "pageview");
</script>
<script type="text/javascript">
  if ((user_email_cookie=readCookie('user_email')) && user_email_cookie.indexOf('@gmail.com')!=-1) {
    createCookie('user_email',(user_email_cookie.replace('@gmail.com','').replace(/\./gi,'').replace(/\+(.*?)$/,''))+'@gmail.com',365);
  }

  if (typeof(readCookie) == "function" && readCookie('user_vocation')) {
    createCookie('u_voc',readCookie('user_vocation'),3000);
  }
  if (readCookie('sapu') == "121") {eraseCookie('sapu');}
  var user_cookie = user_cookie || {};
  eraseCookie("__article_last_size");

if (top.location.pathname == "/" && readCookie('user_id')==957061) {
  var old_SADataCookies = SA.Data.Cookies.get;
  SA.Data.Cookies.get = function(x){if (x=="user_following_users" || x=="user_watchlist_authors") return ""; else return old_SADataCookies(x);}
}
  try{(function(){
    var uc=SA.Data.Cookies.get("user_cookie_key"), t=uc ? uc.match(/t=([0-9]+)/) : null;
    if (t && t[1] < 1367771521) SA.Data.Cookies.set("user_cookie_key","");
  })();} catch(e){}

window.siteon=true;window.acounter=0;//temporary, tell Ilya to delete
</script>
<style>
#embd_slider{
display:none;
}
#top_gainers_wrap .data_currencies_table table {
  width: 100%;
}
#follow_wrap {
  width: 640px;
}

#pro_by_ticker li a {
  max-width:500px;
}
</style> 
<script>
 if (SA && SA.Data && SA.Data.User){
		SA.Data.User.authorResearch = function(){
    return readCookie('author_research_subscriptions') ? readCookie('author_research_subscriptions').split(',') : [];
  }
}
</script>
        </head>
  
  <body class="stretch_bg">

    <script>
  var ms_slug = '';
  var article_dashboards = 'transcript';
  var article_sectors_themes = '@transcripts@us@medical-appliances-equipment@healthcare@article@';
  var ratings_hash={}
  var ARTICLE_ID = 3448766 ;
  var ARTICLE_TYPE = 'transcript';
  var ARTICLE_LOCK = "";
  var availableABVersions=["ver_a"];
  var abOBJ = new ABTest('transcript_pagination', availableABVersions);
  var machine_id = cookieExists('machine_cookie') ? parseInt(readCookie('machine_cookie')) : 0;
  var abVersion = abOBJ.value;
  var sliceSize = 4000;
  var isTranscript = true;
  var insight_sector = null;
  var isWebcast = false;
  var middle_version = ABTest.identity%10;
  var author_tag_id = 96991;
  var author_slug = "sa-transcripts";

  try {window.sessionStorage.setItem("/article/"+ARTICLE_ID, '1');}
  catch (error) {}
</script>
<script>var mone_article_tags = "{aker};;;{healthcare};;;{transcripts,us,medical-appliances-equipment};;;{sa-transcripts}"</script>

<script>var ord = Math.floor(Math.random() * 1000000000);</script>
<span class="seeking_alpha_site_title">Seeking Alpha</span>
<script type="text/javascript">
  if (SA.Data.Cookies.get('show_desktop') == '1') {
    var aHTML = [];
    aHTML.push('<div class="mobile_or_full_site">');
    aHTML.push('<span class="mobile_site" onclick="backToMobile();">Click here to view mobile site</span>');
    aHTML.push('<div class="cleaner"></div>');
    aHTML.push('</div>');
    document.write(aHTML.join(""));
  }
  function backToMobile() {
    SA.Data.Cookies.del('show_desktop');
    var url = window.location.href;
    if (url.indexOf('?') > -1){
      url += '&source=show_desktop_false';
    }else{
      url += '?source=show_desktop_false';
    }
    window.location.href = url;
  }
</script>
<div id="header" class="not_logged_in header_nav">
  <div id="logo_and_navigation" class="logo_and_primary_navigation">
    <div id="comment_popup" style="position:relative; left:0; display:none">
  <div id="popup_secondary">
    <div id="inner_popup"></div>
  </div>
</div>    <div class="logo_and_menu_section">
      <div id="header_dropdown">
        <a href="/" id="sa_logo" title="Seeking Alpha" sasource="salogo"></a>
        <div class="header_arrow caret"></div>
        <div class="hdd_wrapper" itemscope="" itemtype="http://schema.org/SiteNavigationElement" role="navigation"><div class="hdd_arrow"></div><ul class="hdd_menu hdd_insights themes"><li class="hdd_header">THEMES</li><li itemprop="name"><a href="http://seekingalpha.com" itemprop="url" sasource="headtab_menu" title="Home">Home</a></li><li class="hdd_sep"></li><li itemprop="name"><a href="http://seekingalpha.com/insight/alternative-investing" itemprop="url" sasource="headtab_menu" title="Alt Investing">Alt Investing</a></li><li class="hdd_sep"></li><li itemprop="name"><a href="http://seekingalpha.com/insight/dividend-investing" itemprop="url" sasource="headtab_menu" title="Dividend Investing">Dividend Investing</a></li><li class="hdd_sep"></li><li itemprop="name"><a href="http://seekingalpha.com/earnings_center" itemprop="url" sasource="headtab_menu" title="Earnings Center">Earnings Center</a></li><li class="hdd_sep"></li><li itemprop="name"><a href="http://seekingalpha.com/etf_hub" itemprop="url" sasource="headtab_menu" title="ETF Hub">ETF Hub</a></li><li class="hdd_sep"></li></ul><ul class="hdd_menu hdd_insights"><li class="hdd_header">&nbsp;</li><li itemprop="name"><a href="http://seekingalpha.com/insight/income-investing" id="income_tab" itemprop="url" sasource="headtab_menu" title="Income Investing">Income Investing</a></li><li class="hdd_sep"></li><li itemprop="name"><a href="http://seekingalpha.com/analysis/investing-ideas" itemprop="url" sasource="headtab_menu" title="Investing Ideas">Investing Ideas</a></li><li class="hdd_sep"></li><li itemprop="name"><a href="http://seekingalpha.com/analysis/macro-view" itemprop="url" sasource="headtab_menu" title="Macro View">Macro View</a></li><li class="hdd_sep"></li><li itemprop="name"><a href="http://seekingalpha.com/analysis/etf-portfolio-strategy" itemprop="url" sasource="headtab_menu" title="Portfolio Strategy">Portfolio Strategy</a></li></ul><ul class="hdd_menu hdd_premium" id="hdd_my_account"><li class="hdd_header">MY ACCOUNT</li><li itemprop="url"><a href="http://seekingalpha.com/account/email_preferences" itemprop="name" sasource="topnav_mouseover" title="Email Settings">Email Settings</a></li></ul><ul class="hdd_menu hdd_premium"><li class="hdd_header">PREMIUM</li><li class="premium_sub_header" itemprop="name"><a href="http://seekingalpha.com/pages/premium_authors" itemprop="url" rel="nofollow" sasource="headtab_menu" title="Premium Authors">Premium Authors</a></li><li><ul class="premium_nav_list"><li itemprop="name"><a href="http://seekingalpha.com/pages/premium_authors?sort=p&amp;order=d" itemprop="url" rel="nofollow" sasource="topnav_mouseover" title="Most Popular">Most Popular</a></li><li itemprop="name"><a href="http://seekingalpha.com/pages/premium_authors?sort=n&amp;order=d" itemprop="url" rel="nofollow" sasource="topnav_mouseover" title="Newest">Newest</a></li></ul></li><li class="hdd_sep"></li><li class="premium_sub_header" itemprop="name"><a href="http://seekingalpha.com/pro/checkout" itemprop="url" rel="nofollow" sasource="headtab_menu" title="PRO">PRO</a></li><li><ul class="premium_nav_list"><li itemprop="name"><a href="http://seekingalpha.com/pro/checkout" itemprop="url" rel="nofollow" sasource="topnav_mouseover" title="Top Ideas">Top Ideas</a></li><li itemprop="name"><a href="http://seekingalpha.com/pro/checkout" itemprop="url" rel="nofollow" sasource="topnav_mouseover" title="First Look">First Look</a></li><li itemprop="name"><a href="http://seekingalpha.com/pro/checkout" itemprop="url" rel="nofollow" sasource="topnav_mouseover" title="Idea Filter">Idea Filter</a></li></ul></li></ul></div>      </div>
      <div class='nav_container_wrap' id='nav_container_wrap'>
  <div id="nav_container" headtab="">
    <div id="navi_cont" >
      <ul id="navi" class="navi">
        <li id='author_research_top_nav' style='display:none'>
          <div id="authors_dropdown">
            <a>My Authors</a>
            <div id="authors_wrapper" class="authors_wrapper"/>
          </div>
        </li>

        <li thistab='portfolio' class="portfolios">
          <a href="http://seekingalpha.com/account/portfolio" sasource="headtabs">Portfolio
            <span id='portfolio_notifications'></span>
          </a>
        </li>
            <li thistab='market_news'>
              <a href="http://seekingalpha.com/news/all" sasource="headtabs">News</a>
            </li>

            <li thistab='analysis'>
              <a href="http://seekingalpha.com/analysis/all" sasource="headtabs">Articles</a>
            </li>

            <li thistab='stocktalks'>
              <a href="http://seekingalpha.com/stocktalks/all" sasource="headtabs">StockTalk</a>
            </li>
        <li thistab='marketplace' id='menu_marketplace_tab'>
          <a href="http://seekingalpha.com/pages/premium_authors" sasource="headtabs" style="display: none" rel="nofollow">Marketplace</a>
        </li>

        <li thistab='pro' class="pro_tab" id="nav_pro_tab">
          <a href="http://seekingalpha.com/account/pro" sasource="headtabs" rel="nofollow">PRO</a>
        </li>

        <li class="right_section">
          <div class="" id="user_settings_wrapper"></div>
        </li>
      </ul>
    </div>
  </div>


  <div style='display:none' class="rta_nav etf_hub">
    <span class="rta_nav_wrap">
      <div>To screen ETFs by asset class, performance, yield and more, check out the <a href="/etf_hub" sasource="etf_performance" >ETF Hub.</a> <a  sasource="etf_performance" href="/etf_hub" id="etf_hub_button">ETF Hub</a></div>
    </span>
  </div>
</div>

    </div>

    <div class="info_and_search_section" id="right_menu">
      <div id="nav_user_settings"></div>
      <div id="site_search">
        <div class="search_box_container_isolated">
  <div class="search_box">
    <form id="search_box_sa_search" method="get" class="linktosym comp search" action="/search/" onsubmit="return false;">
      <fieldset>
        <input type="button" class="search_button" value="" onclick="if ($('autocomplete_sa_search').value!=$('autocomplete_sa_search').title) AutoCompleteSAConfig.Packages.search.Find()" />
        <input id="autocomplete_sa_search" class="input_text text" type="text" value="Search by symbol, author, keyword..." size="25" autocomplete="off" onblur="if($$('.search_box'))$$('.search_box')[0].style.background='';this.style.color=this.value=='' ? '#8D8D8D' : '#000000';handleInput(this,'blur')" onfocus="if($$('.search_box'))$$('.search_box')[0].style.background='#fff';this.style.color='#000000';handleInput(this,'focus')" afteruploadvalue='eFind quotes, people, expressions, transcripts' title='Search by symbol, author, keyword...' class="find_transcripts" />
      </fieldset>
      <input type="hidden" name="source" value="search_general" />
      <input type="hidden" id="autocomplete_sa_hidden_search" name="q" value="" />
      <input type="hidden" id="autocomplete_sa_hidden_avoid_symbol" name="avoid_symbol" value="" />
      <input type="hidden" name="sort" value="date:d" />
      <input type="hidden" name="cx" value="018269914407235029540:cdhc2yeo2ko" />
      <input type="hidden" name="cof" value="FORID:11;NB:1" />
      <input type="hidden" name="goto_search_tab" value="" />
    </form>
    <script type="text/javascript">SeekingAlpha.Initializer.LogAndRun(function () { AutoCompleteSAConfig.Load('search', { Symbols:true, Keywords:true, IframeCover:true, AfterInsert:function () { this.Find(); }, AfterSubmit:function () { this.Find(); }}) });</script>
    <script type="text/javascript" src="//cse.google.com/coop/cse/brand?form=searchbox_018269914407235029540%3Acdhc2yeo2ko&lang=en"></script>
  </div>
</div>

      </div>
    </div>
    <div class="clearfix"></div>
  </div>
  <script type="text/javascript">
      SeekingAlpha.Initializer.LogAndRun(SA.Navigation.Top.init);
  </script>
</div>

<div id="main_container" class="center_pro transcript_page">
    <script>
      if(window.screen.availWidth > 1260 || SA.Utils.Env.isIPad || SA.Utils.Env.isAndroid) $('main_container').addClassName('show_left_cont');
    </script>
     <div class='left_cont'>
            <div id="left_top_ad"></div>
        <div class="stickyad_wrapper">
          <div class="item banner160x600" id="fixed_banner160x600"></div>
					 <script type="text/javascript">
							var didCreateAd = false;
              function setAD(){
               if (didCreateAd) return;

							    SA.Utils.Ads.GoogleTag.define("/6001/sek.earnings/reports", [[160,601]],'left_top_ad', {"sz":"160x601","x":["x","x"],"tile":1,"d":["earnings","sectors"],"t":["reports","transcripts","us","medical-appliances-equipment","healthcare","article"],"aid":3448766,"z":1,"a":"sa-transcripts","cnt":["7","20","24","26","31"],"pr":"aker","s":"aker"});

								SA.Utils.Ads.GoogleTag.define("/6001/sek.earnings/reports", [[160,600]],'fixed_banner160x600', {"sz":"160x600","x":["x","x"],"tile":3,"d":["earnings","sectors"],"t":["reports","transcripts","us","medical-appliances-equipment","healthcare","article"],"aid":3448766,"z":1,"a":"sa-transcripts","cnt":["7","20","24","26","31"],"pr":"aker","s":"aker"},{sticky: true});

                Mone.article_shown_left_ad = true;
								didCreateAd = true;
              }
              if(window.screen.availWidth > 1260 || SA.Utils.Env.isIPad || SA.Utils.Env.isAndroid) setAD();
           </script>
        </div>
          </div>
  <div id="content_wrapper" itemscope itemtype="http://schema.org/Article" class="article_pages">
    <img src="//staticseekingalpha.a.ssl.fastly.net/images/universal/print_logo.png" width="48" height="20" id="print_seekingalpha_logo" />
     <div id="main_content" class='no_big_gaps_main_content'>
      <div id="" class="no_big_gaps_secondary_ads">
        <div id='article_top_info'>
    <a href='/author/sa-transcripts' sasource='auth_header_pic'><img id='author_info_img' class="author_img" align="center" src="//staticseekingalpha1.a.ssl.fastly.net/images/users_profile/000/101/639/big_pic.png?1361390405" width="66px" height="66px" /></a>
    <div class='info_content'>
      <div>
        <a itemprop="author" class='author_name' href='/author/sa-transcripts' id='author_info_name' rel='author' sasource='auth_header_name'>SA Transcripts</a>,
            <span  >
              <a class='author_nick link' href="http://seekingalpha.com/analysis/transcripts/all?source=article_author_top" target='_blank' onclick='if (!/@seekingalpha.com/.test(SA.Data.User.email())) Mone.event("article", "auth_header_link", "click", {data: {"url":"http://seekingalpha.com/analysis/transcripts/all","text":"Recent earnings call transcripts","author_id":44211,"name":"SA Transcripts","bio":"We cover over 5K calls/quarter"}})'>
                Recent earnings call transcripts
              </a>
            </span>
          <span class="clicks">(44,149 clicks)</span>
      </div>
      <div>
        <span class='author_desc'>We cover over 5K calls/quarter</span>
      </div>
      <div class="bottom_line">
        <a href='/author/sa-transcripts' sasource='auth_header_profile' class="author_action">Profile</a><span class='sep'>|</span>
        <span class='author_action' onclick='Messaging.sendMessagePopup("1aoxskmd","article_auth_header")'>Send Message</span><span class='sep' id='hider'>|</span>
        <div id="mover" class="di">
          <span id="rollover_menu" style="display: none;" onmouseleave="ArticlePage.hideRolloverMenu()">
            <div class="arrow"></div>
            <span id="rollover_content">
              <div class="rta_bottom">
                <div class="m_pop point_left" id="promotion_box_rel">
                  <div id="close_rollover" class="tr cp pr10 pt2">x</div>
                    <div class="m_pop_inner">
                      <div class="popup_header">Author Following Options:</div>

                      <div class="premium_research_header" style='display:none'>
                        <div class="popup_row_header">
                          <div class="preloader_popup_ab" style="float: left;">
                            <input type="checkbox" id="author_research_learn_more" class="author_research_check" style="margin-right: 5px;">
                          </div>
                          
                        </div>
                        <div class="popup_row_footer">
                          &nbsp;<a class="bold" target='_blank' sasource='follow_top_learn_more' href="/account/research/subscribe?slug=sa-transcripts&source=follow_top_learn_more">Learn more»</a>
                        </div>
                      </div>

                      <div class="popup_row_first">
                            <div class="popup_row_header">
                              <div class="preloader_popup_ab" style="float: left;">
                                <input type="checkbox" id="follow_author_checkbox" style="margin-right: 5px;">
                              </div>
                              Follow this author
                            </div>
                          <div class="popup_row_footer">See their articles on your Seeking Alpha homepage and in your feed.</div>
                        </div>
                        <div class="popup_row_second">
                          <div class="popup_row_header">
                            <div class="preloader_popup_ab" style="float: left;">
                              <input type="checkbox" id="get_rta_author_checkbox" style="margin-right: 5px;">
                            </div>
                            <div id="max_rta_header">Real-time alerts on this author</div>
                          </div>
                          <div id="max_rta_footer" class="popup_row_footer">Get their new articles emailed to you as they are published.</div>
                        </div>
                        <div class="popup_row_last">
                          <div class="popup_row_header">
                            <div class="preloader_popup_ab" style="float: left;">
                              <input type="checkbox" id="subscribe_digest" style="margin-right: 5px;">
                            </div>
                            Daily digest on all my authors
                          </div>
                          <div class="popup_row_footer">Get all your favorite authors’ new articles emailed to you in one daily digest.</div>
                        </div>
                    </div>
                  <div class="cleaner"></div>
                </div>
              </div>
            </span>
          </span>
          <span id="msg_popup"></span>
          <span id='follow_btn' class="follow_button_author" onclick="ArticlePage.toogleFollowAuthor('article_auth_header')" onmouseover="ArticlePage.showRolloverMenu()"></span>

          <span id="ballon_container"></span>

          <span id="follow_only_top"></span>
          <span class='clicks'>
            (<span id='follow_clicks' class='follow_clicks_author'>6,668</span> followers)
          </span>
        </div>
      </div>
      <div class='arr_up'></div>
    </div>
    <script>
      setArticleTopABTest();
      SA.Pages.Article.Follow.init('sa-transcripts');


      Mone.articleAuthorLinkShown = true;

      function setEvents(){
        var marketing_unit = $('author_research_learn_more');
        if (marketing_unit) marketing_unit.observe('click', listEvents);
      }

      function listEvents(e){
        if (e.target.hasClassName('author_research_check')){
          SA.Utils.SASource.setNext('follow_top');
          window.open("/account/research/subscribe?slug=sa-transcripts&source=follow_top", '_blank' );
          if (e.target.checked) e.target.checked = false;
        }
      }

      function setArticleTopABTest(){
        if (!window.is_active_research_author || !$('article_top_info') || SA.Data.Cookies.get('author_slug') == window.author_slug) return;

        var test_value = ABTest.tenth, test_version, author_name = $('author_info_name').innerHTML, subscribe_link = '/account/research/subscribe?slug='+ window.author_slug + '&source=article_top_author_banner';
        $$('#article_top_info .info_content div')[0].update($('author_info_name').cloneNode(true));

        if (test_value){
          test_version = 'ver_1';
          $$('#article_top_info .info_content div')[0].insert("<a class='premium_research_button' href='"+subscribe_link+"'>Premium Research &raquo;</a>");
        }
        $('article_top_info').addClassName(test_version);
      }

      SeekingAlpha.Initializer.onDOMLoad(function(){ setEvents();});

    </script>
</div>




      </div>
       <div id='top_author_details'>
         <div id="article_header" class="article_content">
  <div class="top_content">
    <div id="page_header" class="page_header_email_alerts">
      <h1>
        <span itemprop="headline">Akers Biosciences&#x27; (AKER) Management Discussion on Q2 2015 Results - Earnings Call Transcript</span>
              </h1>
      <div id="article_info">
        <div class="article_info_pos">
          <span itemprop="datePublished" content="2015-08-18T16:55:09Z">Aug. 18, 2015 12:55 PM ET</span>
          <span id='title_article_comments'></span>
          <span class="print_hide"><span class='print_hide'>&nbsp;|&nbsp;</span> <span>About:</span> <span id='about_primary_stocks'><a href="/symbol/AKER" title='Akers Biosciences Inc.' sasource='article_primary_about_trc'>Akers Biosciences Inc. (AKER)</a></span></span>
          <span class="author_name_for_print">by: SA Transcripts</span>
            <span id="second_line_wrapper"></span>
        </div>
        <div class="article_disclosure">
          <div id="article_body_top2" class="disclosure_top" style="display:none;"></div>
        </div>
      </div>
    </div>
  </div>
</div>
<div class="cleaner"></div>

       </div>
        <div id="article_body_container" class="no_big_gaps_article_body_container">
          <div id="article_body" itemprop="articleBody">
            <div id="article_participants" class="content_part hid">
  <p>Akers Biosciences Inc. (NASDAQ:<a href='http://seekingalpha.com/symbol/aker' title='Akers Biosciences Inc.'>AKER</a>)</p>
<p>Q2 2015 Results Earnings Conference</p>
<p>August 18, 2015, 09:00 AM ET</p>
<p><strong>Executives</strong></p>
<p>Ben Simons - Investor Relations </p>
<p>Ray Akers - Co-Founder and Executive Chairman</p>
<p>Gary Rauch – Vice President of Finance, Controller</p>
<p><strong>Analysts</strong></p>
<p>Ram Selvaraju - Rodman</p>
<p>Jules Augus - Aegis Capital</p>
<p>Marc Robins - Catalyst Research</p>
</div>

<div id="article_content" class="content_part hid">
  <p><strong>Operator</strong></p>
<p>Good morning, and welcome to the Akers Biosciences' Second Quarter and First Half 2015 Earnings Conference Call.</p>
<p>As a reminder, this conference call is being recorded. I would now like to introduce your host for today's conference, Ben Simons with Akers Investor Relations team. Ben, please go ahead.</p>
<p><strong>Ben Simons</strong></p>
<p>Thanks, Stephaney. Good morning, everyone and thank you for joining us. On call today, we have the Co-Founder and Executive Chairman, Dr. Ray Akers; and the VP of Finance, Gary Rauch.</p>
<p>Following the Safe Harbor statement that I will read, then Ray will provide an overview of the business and of the operational developments in the first quarter. And then Gary will provide a summary of the financial results before we open up the call for questions.</p>
<p>Before we get underway, I would like to very briefly ask everyone to take note of the Safe Harbor paragraph that appears at the end of the news release, detailing the company's financial results, which were published this morning.</p>
<p>The paragraph states that any forward-looking statements that the company makes, speak only as of the date made, are subject to inherent risks and uncertainties, including those described in the company's report filed with the Securities and Exchange Commission and should not be unduly relied upon.</p>
<p>Except as otherwise required by Federal Securities laws, the company disclaims any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein or elsewhere to reflect any change in our expectations, with regard to any changes in events, conditions or circumstances on which any statement is based.</p>
<p>With that, I would now like to hand over the call to Akers Bio's Co-Founder and Executive Chairman, Ray Akers.</p>
<p><strong>Ray Akers</strong></p>
<p>Thank you, Ben. And good morning, everyone. Thank you for joining us. For the benefit of anyone on the call, who is new to Akers Bio, I’ll give you a two-minute overview of the business.</p>
<p>The underlying principal of our company is to utilize our proprietary technology developed over 20 years to help reduce the cost of healthcare by developing and selling faster, easier diagnostic tests. We develop proprietary technologies, which can be used in many different medical tests some of which we commercialized and some of which we are still working on in the lab.</p>
<p>With all of our products have in common is that they are rapid point of care tests, they give results almost instantly, they are single-use devices, they are less invasive in a tests which they are designed to replace and they have the capacity to save money for the healthcare system.</p>
<p>Furthermore, faster diagnosis means faster more accurate treatment for patients simply put, we figure out how to make faster, easier and less expensive versions of current health and medical tests with our independent technologies and that makes healthcare better. We are targeting large segments of the diagnostic market where the impact of our test could be significant.</p>
<p>These areas include coagulation, diabetes, respiratory diseases such as lung cancer, infectious diseases such as Chlamydia, cardiovascular diseases such as heart attacks, and the huge consumer focused health and wellness markets, which I will mention later on.</p>
<p>Our primary focus at present is on driving the sales of the flagship test for an allergic condition associated with the blood thinner heparin. This is a good example of what we do. We make the only rapid test to detect the potentially fatal condition known as HIT or Heparin-Induced Thrombocytopenia.</p>
<p>We estimate our test has a capacity to save the average U.S. hospital well over $1 million a year. That’s not just because our tests cost less than the existing laboratory methods, but because by providing a near-instant diagnosis we can save the hospital a significant amount of money on the use of unnecessary medicines and hospital time or waiting for a lab to send back test results. It’s these cost savings, which will drive domestic sales growth of these tests in months and years ahead.</p>
<p>As a reminder of the potential size of the market for this test, 4 million HIT tests are conducted annually in U.S. laboratories, all of them can be replaced with the Akers Rapid Test and that is before we talk about other markets such as Europe and China. Evidence of these drugs comes from the growing number of sales for this test, which at present is primarily driving the company’s revenues. We are not even scratching the surface of what this test can do in the future, the PIFA Heparin test was responsible for $560,000 of our revenue in Q2, to put that in perspective that 67% more than we did for this test in the same quarter last year.</p>
<p>And we expect the growth to accelerate meaning a stronger second half than first half. Why is that? Quite simply because we now have this financial ability to have sales and marketing representatives across the country who are in turn supporting our distribution partners. We talked to more potential customers than we ever can do before we had the cash infusion from the 2014 NASDAQ IPO and our experience shows the more customers we can get in front and demonstrate the value of this test to, the more who buy it. We also implemented price increases, which will start to implement revenue towards the end of this year or early next year.</p>
<p>What I just talked about is only domestic business for HIT test; there is significant potential upside from China with a test waiting regulatory approval from Chinese FDA and also from other countries around the world.</p>
<p>Another interesting development in the quarter is return of demand for our alcohol breathalyzers in Europe, this business had previously dried up in France when the French government did a You-turn on the fine, which was to be imposed on drivers failing to posses breathalyzers in their vehicles. I’m pleased to see that we’re now seeing a gradual recovery of demand not necessarily from France but from new customers in Europe for these alcohol breathalyzers.</p>
<p>We saw $169,000 in Q2 and $210,000 in the first half of the year, with the pipeline of orders for this product through the remainder of the year should be exponentially better than the first half. One of the most significant events to occur in terms of the company’s future direction has been the creation of the Akers wellness product line and the introduction of its first transformative breath test known as BreathScan OxiChek and BreathScan KetoChek.</p>
<p>These test can [indiscernible] on a mobile device, they will enable doctors, care, suppliers of nutritional supplements, health coaches and consumers themselves to monitor trends in critical metabolic processes with the level of convenience which has never before been available to them, wellness is a huge market globally particularly in the U.S. and our proprietary technology for identifying biomarkers in breath positions us very well to capitalize on it.</p>
<p>Why would you want to use blood or urine when you can breathe into a tool for a few seconds instead. So that is a brief summary of activity in the second quarter, I will be very happy to answer questions shortly, before that however I’m going to turn it over to Gary to briefly walk you through the financial highlights and then I will make a few closing comments. Gary?</p>
<p><strong>Gary Rauch</strong></p>
<p>Thanks Ray. It is worth taking a minute to explain very much like other medical device companies in their early phases of commercialization, our revenues are uneven as we receive initial stocking awards from new distributors in new countries. The effect is that until consistent ordering patterns are established, it’s inevitable that the company of our size and stage will have some quarters where sales are lighter than others due to the timing of product shipments to new markets.</p>
<p>We expect this trend to continue until our products are more established in the countries, for example we are very confident receiving growing orders from China for certain products and other international products or markets but the timing which is often dependent on external factors such as regulatory approval is not within our control. In Q2 the majority of the revenue came from domestic sales of the Heparin allergy test and the quarter did not benefit from any initial stocking orders like those that we hope will come in future.</p>
<p>The 29% reduction in revenue for the quarter compared to Q2 2014 is mainly due to their previous quarter having benefited from the initial stocking order of the Cholesterol Test for the Middle East. Third revenue for the quarter was $967,000 if you strip out the initial Cholesterol test order from Q2 last year worth 860 and just compare quarters on like-for-like basis we did much better this quarter then in Q2, 14 in fact just little under 100% better. This shows that the underlying core business particularly in Heparin allergy test is moving in the right direction.</p>
<p>Our overall gross margin percentage was 65% as compared to 89% in Q2 2014 but you can comparably the margins on a like-for-like basis because Q2 14 is unusually high margin was influenced by the sales of the after the mentioned cholesterol test which had previously been written off on our books and therefore sold for a 100% profit margin.</p>
<p>We can see the margin is settling around the level that I would - in the 60% to 65% range which is a healthy place to be. The company made a gross profit on those revenues is $626,000 in the quarter after administrative sales research and exceptional cost, the company’s recorded a loss before income tax is less than $2.1 million and that compares to a loss before income tax of about $0.5 million in the same period last year which was as I just explained influenced by unusually high gross margin. The last results infected by the establishment of the reserve for allowance of around $860,000 on a receivable that due to June 30, 2015.</p>
<p>The basic and diluted loss per common share was $0.41 compared to $0.10 for Q2 last year for the same reasons I just described. I’ll talk you through the main cause briefly. General and administrative expenses were $1.75 million which was 72% higher than the same quarter last year this line includes the $860,000 allowance I described earlier and explains the unusually high cost in Q2.</p>
<p>Sales and marketing expenses were 553,000 which was 40% up from Q2 last year due to relatively significant expansion of our sales and marketing personnel and research and development cost were around 378,000 which was 52% more than Q2 last year mainly due to the increase in professional service cost associated with preparing several key products for the marketplace.</p>
<p>We ‘re maintaining a strong balance sheet as a resulted cash infusion for the January 2014 NASDAQ IPO and we had cash and marketable securities at the end of the quarter of $6.7 million.</p>
<p>I’ll now turn the call back over Ray to add some closing comments.</p>
<p><strong>Ray Akers</strong></p>
<p>Thank you, Gary. Before I take question let me remind overall operational priorities. First our newly expanded sales and marketing team has been tasked to unlock the growth potential of heparin allergy test in the U.S. and they’re beginning to do that.</p>
<p>Second we will assist our growing number of distribution partners to establish international sales for the use another tests particularly in China. Third we’re working to establish sales channels for our acres wellness products and either the substantial health and wellness sector including weight loss and anti-aging and will be launching our first consumer facing online store this quarter. And finally we intend to bring to market new disruptive rapid testing solution for conditions chlamydia and diabetic ketoacidosis before this end of this year</p>
<p>Looking ahead through the remainder of the year, most important indicator is the domestic sales of the flagship-hit test continued to arise and we expect this trend to accelerate. We also have a strong pipeline of orders for alcohol breathalyzers coming from new distributors in the EU. Longer term we’re very excited about the prospectus for our international business particularly in China where we see the most significant opportunity.</p>
<p>We have good revenue visibility through the remainder of the year and our core business and we also expect to see initial revenue contributions this year from a wellness line at these transformative products established to replace in the market. Thanks everyone for your support. Gary and I would now be pleased to answer any questions you may have.</p>
</div>

<div id="article_qanda" class="content_part hid">
  <p><strong>Question-and-Answer Session</strong></p>
<p><strong>Operator</strong></p>
<p>Thank you. [Operator Instructions] We’ll go first to Ram Selvaraju.</p>
<p><strong><span class="question">Ram Selvaraju</span></strong></p>
<p>Hi, gentlemen. Thanks very much for taking my questions. Couple of questions for you Ray and then may be one or two for Gary. First, will respect to the distribution arrangement for the breathalyzer test, you anticipate getting a replacement distribution arrangement like that one that you originally had with ChubeWorkx or are you going to go in a more direct route or use perhaps a number of different distributors in order to access this market ex-US.</p>
<p><strong><span class="answer">Ray Akers</span></strong></p>
<p>Well, thanks, Ram, and good to talk to you again. This is Ray. We have built a distribution network now that touches 30 countries and so we’re going to use that one. We believe that’s the best path success is to go country-by-country because I belief that every market is local. And that’s where the orders that have we have in hand now which are into the seven figures now, have come from.</p>
<p><strong><span class="question">Ram Selvaraju</span></strong></p>
<p>Okay. And with respect to the French market specifically, I understood from your comments and from the press release that the French government postponed applying the fine of the originally planned to levy on drivers who didn’t have these breathalyzers in their cars. How do you anticipate that picture changing going forward, i.e., is there a timeline in place within which to fine is likely to be imposed and if so what impact if any could that have on sales as reportable breathalyzer product.</p>
<p><strong><span class="answer">Ray Akers</span></strong></p>
<p>The French government has not given any indications what their intentions are at the end of the day with regard to enforcing the original law. However, what they have done is put a new law into discussion that will require drivers under the age of 21 to carry these things. And we believe that’s going to be enacted within the next six months that should start that market up again. If you remember one of the reasons why the French government suspended that law was because there was not enough supplier breathalyzer to meet the demand across the whole country.</p>
<p>So it may be possible that they are going to stage it, and let the supply build up and maybe possible that they are just going to end it right with 21 year olds and under. We really don’t know. But we do expect some time next year for those sales has start to pick up again.</p>
<p><strong><span class="question">Ram Selvaraju</span></strong></p>
<p>Okay. That’s very helpful. And then a question on the US market for the monitor key tone, do you anticipate that the bulk of this product opportunity is in the diabetic population or in the patient population may not necessarily have an ongoing disease indication that they need to manage but just want to maintain some kind of control from kind of checking ability on their key tone levels.</p>
<p><strong><span class="answer">Ray Akers</span></strong></p>
<p>So your question relates to both being in diabetics, is that right?</p>
<p><strong><span class="question">Ram Selvaraju</span></strong></p>
<p>Yes.</p>
<p><strong><span class="answer">Ray Akers</span></strong></p>
<p>Yes, okay. So I think that the market is pretty clear, the American Diabetes Association recommends that a key tone test must be performed anytime that hits 250 as blood glucose level and when that happens there at risk for [indiscernible] doses. So I think that’s the metric that’s going to be used to tell people that they need to run this test. Currently right now, it’s not adhered to very well much of this - endocrinologists some of because that the test trips are pretty expensive, and the year-end tests are really not that clinically relevant and so we think that we’ve got a solution that works for those recommendations.</p>
<p><strong><span class="question">Ram Selvaraju</span></strong></p>
<p>Okay. That’s very clear. Couple of questions I had for Gary, just to go through them as quickly as I can. Firstly, can you comment on the extent of stock based compensation recorded this quarter? And how you anticipate stock based compensation to evolve going forward and then secondly with respect to general and administrative expenses, is there any guidance you can provide to us regarding what you anticipate the total G&amp;A spend to be this year and how you anticipate potentially evolving for example for next year?</p>
<p><strong><span class="answer">Gary Rauch</span></strong></p>
<p>Okay. Well on the first one there, there were no stock options granted during the second quarter, there were board related options granted in January of this year. As far as going forward as per the last meeting with the board discussions had been carried out on the issuance of additional stock options but no decisions have been made at this point. So I honestly don’t know how to answer that for the rest of the year. As far as administrative expenses go I’m going to guess that there are going to be in around the $2.5 million to $3 million mark for the year taking into account this 864 that we reserved for the bad debt receivable.</p>
<p><strong><span class="question">Ram Selvaraju</span></strong></p>
<p>Okay. Can you just give me a little bit of clarity regarding bad debt receivable, at what point is it going to be sort of written off, at what point you have basically have [indiscernible] on what that is?</p>
<p><strong><span class="answer">Gary Rauch</span></strong></p>
<p>Well to be honest with you right now, I don’t believe any items that is actually going to be written off this was an event that caught us by surprise, we received some information that basically let us to reevaluate the receivable and because of the accounting requirements, we decided it was definitely a material significant event and decided to go ahead and post the receivable quite conservative.</p>
<p><strong><span class="question">Ram Selvaraju</span></strong></p>
<p>Okay, got it. Okay thanks very much.</p>
<p><strong><span class="answer">Gary Rauch</span></strong></p>
<p>And as of this point we just don’t have enough information to make a decision on that.</p>
<p><strong><span class="question">Ram Selvaraju</span></strong></p>
<p>Okay, I’ll jump back in the queue, thank you.</p>
<p><strong>Operator</strong></p>
<p>We’ll go to Jules Augus with Aegis Capital.</p>
<p><strong><span class="question">Jules Augus</span></strong></p>
<p>Good morning, Ray.</p>
<p><strong><span class="answer">Ray Akers</span></strong></p>
<p>Good morning.</p>
<p><strong><span class="question">Jules Augus</span></strong></p>
<p>Can you hear me?</p>
<p><strong><span class="answer">Ray Akers</span></strong></p>
<p>Yes Jules. I can.</p>
<p><strong><span class="question">Jules Augus</span></strong></p>
<p>Okay. I have couple of questions here, will your company possibly need additional financing of the near to medium term?</p>
<p><strong><span class="answer">Ray Akers</span></strong></p>
<p>No.</p>
<p><strong><span class="question">Jules Augus</span></strong></p>
<p>Okay. Also do you have any idea or can you comment about the sales volume you need to be at a breakeven point?</p>
<p><strong><span class="answer">Ray Akers</span></strong></p>
<p>Yes Jules our breakeven point is just little over $7 million in revenue.</p>
<p><strong><span class="question">Jules Augus</span></strong></p>
<p>Okay and that would be your cash flow breakeven?</p>
<p><strong><span class="answer">Ray Akers</span></strong></p>
<p>Yes absolutely.</p>
<p><strong><span class="question">Jules Augus</span></strong></p>
<p>All right, thank you.</p>
<p><strong><span class="answer">Ray Akers</span></strong></p>
<p>Thank you. Thank you for your support. Any other question?</p>
<p><strong>Operator</strong></p>
<p>We’ll go to our next question from Marc Robins with Catalyst Research.</p>
<p><strong><span class="question">Marc Robins</span></strong></p>
<p>Hi thank you very much. Good morning gentlemen.</p>
<p><strong><span class="answer">Gary Rauch</span></strong></p>
<p>Hi Marc.</p>
<p><strong><span class="question">Marc Robins</span></strong></p>
<p>Hi Gary, following up on that last question that is $7 million on an annual basis, correct?</p>
<p><strong><span class="answer">Gary Rauch</span></strong></p>
<p>Yes.</p>
<p><strong><span class="question">Marc Robins</span></strong></p>
<p>Okay, thank you. Just wanted to make sure we thought of that, size of the market for the blood glucose test, it is not a blood glucose test, it is a Ketone test and it might be prescribed to be used as a blood glucose level is above 250, you have an estimate as to how large that Ketone test is for strips and anything else might be in the market.</p>
<p><strong><span class="answer">Gary Rauch</span></strong></p>
<p>Sure Marc I will tell you from experience, so just to be clear, our test works with breath and of course breath is directly reflected in the blood. So we can say what the blood Ketone levels are by analyzing the breath, in the clinical trial that we have run on Type 1 diabetics they average about one test per week what that really means though if they add two episodes per month because when they have an episode they - two is positive [indiscernible] would do to fix the condition and then they go into second to make sure that they return to a negative state. So in the U.S. there are about three million diabetics so that would translate to a market of about 150 million tubes a year each share completely saturated the market and our selling price on that test is $2 a piece. That will give you the size of the market, size in Europe is about the same.</p>
<p><strong><span class="question">Marc Robins</span></strong></p>
<p>Very good thank you, I appreciate it. And then the other question I had this one is for your CFO and just kind of a follow up on question that was brought up earlier regarding stock options and stocks grants you think that something that we had prepared for on an annual basis come every January is that something or do you think that’s going to be more regular event and we’re going to have kind of guess for each quarter.</p>
<p><strong><span class="answer">Gary Rauch</span></strong></p>
<p>No, I think and it was just my personal opinion obviously I can’t speak to the board of directors but I would believe that it’s probably going to be an annual event for compensation of the key employees and also for the board.</p>
<p><strong><span class="question">Marc Robins</span></strong></p>
<p>Okay and so there might be some kind of adjustment later than this year but then we should be going to an annual kind of an event situation for 2016 and beyond?</p>
<p><strong><span class="answer">Gary Rauch</span></strong></p>
<p>That’s correct.</p>
<p><strong><span class="question">Marc Robins</span></strong></p>
<p>Okay , very good and help me understand and this was really kind of an interesting facet and I have to apologize for being so even about the company but what fascinated me as is the you had written of your Cholesterol Test, I guess that was a year ago and then took a 100% of course it was a 100% gross margin help me understand where the Cholesterol Test is I mean is that a product that you don’t think as much viability in the future enhance the write off was getting to the point where it was aged inventory, give me a little background if you would so I can understand that?</p>
<p><strong><span class="answer">Ray Akers</span></strong></p>
<p>Sure, this is Ray so we do believe this is about a product and a core product of ours, cardiovascular disease and high Cholesterol is ramped all around the world and yet you see especially in places in the Middle East and in the far east or diets are rapidly westernizing and the metabolism of people there can handle high [indiscernible] with theses, it needs the very high Cholesterol levels and in places like China 50% of all debt there are through [indiscernible] stroke so it’s a really increase problem and our test is that indented to replace as sophisticated liquid profile that you might had done here in the states or in Western Europe.</p>
<p>But its intended as a quick screen and it’s also intended to it was diagnosed high Cholesterol in those areas of the world where laboratory infrastructure is does not exist or its very minimal so we do believe that this test is going to be a hit we’ve got really very positive feedback from many distributors in those parts of the world. This one time reserve was taking simply because this receivable is old and that the product does not get have approval so that’s where we did what we did.</p>
<p><strong><span class="question">Marc Robins</span></strong></p>
<p>Okay. Thank you and one thing that you said that I thought was really interesting about products that are on the horizon is for I believe bloods thinness, okay is that replacement for the what is that IMP, INT whatever the test is at the folks on [indiscernible] have to take every month?</p>
<p><strong><span class="answer">Ray Akers</span></strong></p>
<p>No, the test that we have deducts a rooted condition to those widely used [indiscernible] world called Heparin.</p>
<p><strong><span class="question">Marc Robins</span></strong></p>
<p>No, not that’s the Heparin. I understand that, I thought maybe I heard in your opening remarks that there was another test that could replace the pin correct.</p>
<p><strong><span class="answer">Ray Akers</span></strong></p>
<p>No, what we reported the test that’s commonly used for cumulative, however we are looking at that building other test of coagulation line to flush that coagulation market that we’ve opened up for Heparin.</p>
<p><strong><span class="question">Marc Robins</span></strong></p>
<p>Okay and then lastly talking about the your alcohol breathalyzer test, Brazil has just put through one of the most strict drug testing - in the world for truckers and they all have to be tested I think once every two years and specifically it’s been, it’s a hair test which is kind of interesting have you heard any trends where alcohol testing might be in the - country Brazil?</p>
<p><strong><span class="answer">Ray Akers</span></strong></p>
<p>We don’t have distribution partner here yet, so we’re not really in that market.</p>
<p><strong><span class="question">Marc Robins</span></strong></p>
<p>Okay. Very good. Thank you. I’ll get back in the queue.</p>
<p><strong><span class="answer">Ray Akers</span></strong></p>
<p>Okay.</p>
<p><strong>Operator</strong></p>
<p>[Operator Instructions] We’ll take our next question from Ram Selvaraju with Rodman.</p>
<p><strong><span class="question">Ram Selvaraju</span></strong></p>
<p>Yes. Thanks very much for taking my follow-up. Ray, I just wanted to clarify what the ISO-1345 specification means in ex-US markets for acceptance of your products and repeatidity with which you could get regulatory clearance, so if you could clarify that or switch?</p>
<p><strong><span class="answer">Gary Rauch</span></strong></p>
<p>Sure. There are many countries that do not recognize the FDA approvals or for that matter even - in the European Union, here we have everyone around the world recognizes ISO-1345 which is the international quality standard for medical devices. So what it does is allows you to speed up the regulatory process in many parts of the world, India being one of them. And that’s the key because otherwise if you don’t have that ISO certificate that typically then leads to a audit or inspection of your quality system which can take a long time. So that’s the whole reason for getting it, it’s a new and better discipline for a company here in terms of quality system but it also had the big effect in certain markets.</p>
<p><strong><span class="question">Ram Selvaraju</span></strong></p>
<p>Got it. Thank you very much.</p>
<p>End of Q&amp;A</p>
<p><strong>Operator</strong></p>
<p>And that concludes today’s Q&amp;A session. I would now like to turn the call back to our speakers.</p>
<p><strong>Ray Akers</strong></p>
<p>Well, we would like to thank everyone for their questions and their time this morning and we also very much appreciate your support and look forward to updating you with further progress on our Q3 earnings call. Thank you and have a great day.</p>
<p><strong>Operator</strong></p>
<p>And that concludes today's conference call. Thank you for your participation.</p>
</div>

<div id="article_disclaimer" class="content_part hid">
  
<p><strong>Copyright policy: </strong>All transcripts on this site are the copyright of Seeking Alpha. However, we view them as an important resource for bloggers and journalists, and are excited to contribute to the democratization of financial information on the Internet. (Until now investors have had to pay thousands of dollars in subscription fees for transcripts.) So our reproduction policy is as follows: <strong>You may quote up to 400 words of any transcript on the condition that you attribute the transcript to Seeking Alpha and either link to the original transcript or to www.SeekingAlpha.com. All other use is prohibited.</strong></p>

<p>THE INFORMATION CONTAINED HERE IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL, CONFERENCE PRESENTATION OR OTHER AUDIO PRESENTATION, AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION, THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE AUDIO PRESENTATIONS. IN NO WAY DOES SEEKING ALPHA ASSUME ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S AUDIO PRESENTATION ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.</p>
<p>If you have any additional questions about our online transcripts, please contact us at: <a href="mailto:transcripts@seekingalpha.com" rel="nofollow"><u>transcripts@seekingalpha.com</u></a>. Thank you!</p>

</div>

<div id="article_slice"></div>

<div class="cleaner"></div>

          </div>
          <div class="cleaner"></div>
          <div id="trafic_driver_alt_invest">
            <script>SA.Utils.Ads.marketing("trafic_driver_alt_invest", 'articles', 1, {"aid":3448766,"d":["sectors"],"t":["transcripts","us","medical-appliances-equipment","healthcare","article"],"s":["aker"],"pr":"aker","z":1,"a":"sa-transcripts","cnt":["7","20","24","26","31"],"ldr":[]});</script>
          </div>
          <div class="cleaner"></div>
          <div class="transcript_bottom_tabs">
            <ul id="tab_cmd" style="float:left;display:none;">
              <li id="tab_single_bottom" name="tab_single" style="border-width:0px !important;" onclick='singlePageView()'><span>Single page view</span></li>
              <li id="tab_search_bottom" class="last chosen" name="tab_search" style='display:none;border-left: 1px solid #C4C4C4;'><span>Search</span></li>
            </ul>
            <div id="pag_cmd" style="display:none;">
            	<div id="tab_prev_bottom" name="tab_prev" style="display:none;float:left"><a href="javascript:void(0)" onclick="abOBJ.convert('Prev Page');trascriptNextSlice(-1)">&laquo; Previous</a>&nbsp;|&nbsp;</div>
            	<div id="tab_pagination" style="float:left"> page <span id="current_page_index">1</span> / <span id="last_page_index"></span></div>
            	<div id="next_page" style="display:none;">|&nbsp;<a href="javascript:void(0)" onclick="abOBJ.convert('Next Page');trascriptNextSlice(1)">Next »</a></div>
            </div>
            <div class="cleaner"></div>
          </div>
          <script>OpenTranscriptPage();</script>
          <div id="content_follow_up" class="transcript_follow_up">
            <div id="paging" class="transcript-paging"></div>
            <div id="article_bottom_about" class="article_bottom_units"></div>
            <div id="pro_by_ticker"></div>

            <div class="share_this_page_article_bottom">
              <ul id="page_toolbar" class="page_toolbar">
  <li class="share_this_page_article_toolbar">
    <div class="share_this_page_snippet">
  <div id="first_line_info" style="width:490px">
    <div class="left"><h6><span id="share_slogan" class="fs16">Share this transcript with a colleague</span></h6></div>
  </div>
  <div class="widgets">
    <!-- Email -->

      <span class="email_this" onclick="email_story_to_friends('Article',3448766,'http://seekingalpha.com/article/3448766-akers-biosciences-aker-management-discussion-on-q2-2015-results-earnings-call-transcript')">
        <div class="email_button"></div>
        <div class="email_bubble">
          <span id="widget_email_count"></span>
          <span class="cor_right"></span>
        </div>
      </span>
    <!-- twitter -->
    <span class="twitter_small">
        <a href="https://twitter.com/share" class="twitter-share-button twitter_share" data-text="Akers Biosciences&#x27; (AKER) Management Discussion on Q2 2015 Results - Earnings Call Transcript http://seekingalpha.com/article/3448766-akers-biosciences-aker-management-discussion-on-q2-2015-results-earnings-call-transcript?source=tweet $AKER" data-related="salphatrending" data-url=" " data-counturl="http://seekingalpha.com/earnings_center/all/article/3448766" data-count="horizontal">Tweet</a>
    </span>
    <!-- Linked In -->
      <span id="linkedin_1" class="linkedin_small linkedin_share"><script type="IN/Share" data-counter="right" data-onsuccess="linkedin_callback" data-url="http://seekingalpha.com/earnings_center/all/article/3448766?source=linkedin_share"></script></span>
    <!-- facebook -->
    <span id="span_fb_widget_like" class="facebook_small facebook_share"><div class="fb-like" data-href="http://seekingalpha.com/earnings_center/all/article/3448766?source=facebook" data-send="false" data-layout="button_count" data-show-faces="false" data-font="tahoma"></div></span>
    <div id="span_fb_widget_share" style="display: none;margin:0 10px 0 0;" class="fb-like fl" data-href="http://seekingalpha.com/earnings_center/all/article/3448766?source=facebook" data-layout="button" data-action="like" data-show-faces="false" data-share="false"></div>
    <!-- Plusone  -->
      <span id="pluszone" class="plusone_wrap"><span class="plusone plusone_share"><div class="g-plusone" data-size="medium" annotation="bubble" data-width="65" data-callback="plusone_callback"></div></span></span>
    <!-- print -->
      <span class="print_this" onclick="print_article('with_comments')"><Print><div class="print_button"></div></span>
  </div>
</div>

  <script>
     //FB Share button test
     $('span_fb_widget_like').hide();
     $('span_fb_widget_share').show();
     setTimeout(function(){$('span_fb_widget_share').style.background="none";}, 15000);
     $('pluszone').setStyle({'margin-left':'5px'});


    SeekingAlpha.Initializer.AddAfterLoad(function(){
      new Ajax.Updater({success: 'widget_email_count'}, '/form/ajax_get_email_count', {
        method: 'get',
        parameters: {
          item_name: 'Article',
          article_id: '3448766'
        }
      });
    });

  </script>

  </li>
</ul>
            </div>
            <div class="cleaner"></div>
            <div class="comments_with_more">
              <div id="comments_section">
              </div>
            </div>

            <div id="bottom_rta_unit" class="cb"></div>

          </div>
        </div>
    </div>
<div class="article_right_content">
	  <div id="ads_and_tools" class="article_sidebar_tools red_sidebar">
    <div id='earnings_sticky'>
    	<div class="insight_back_link">
      	Back to:<br/>
      	<a href="/earnings_center/transcripts" sasource="earnings_back_link">
        	EARNINGS TRANSCRIPTS &raquo;
      	</a>
    	</div>
			<div id='ad_earnings_sticky'></div>
				<script>
				if (!is_pro){
					SA.Utils.Ads.GoogleTag.define("/6001/sek.earningscenter/articles", [[300,250],[300,600]],'ad_earnings_sticky', {"sz":"300x250,300x600","x":"x","tile":2,"d":["earningscenter","sectors"],"pos":"t","t":["articles","transcripts","us","medical-appliances-equipment","healthcare","article"],"aid":3448766,"z":1,"a":"sa-transcripts","cnt":["7","20","24","26","31"],"pr":"aker","s":"aker"},{sticky: true});
				}
			</script>
  	</div>
	</div>
<script>
    if($$('#ads_stick .banner300x600')[0] && $('article_body_container').offsetHeight>1400) {
        if (SA.Data.User.loggedIn()) new stickyAd('ads_stick', {remove_stick_top: 650}).fixed_ads_init();
    }
</script>

</div>

  </div>
  <input id="short_url" type="hidden" value="http://seekingalpha.com/a/21x32" />
</div>
<div id='footer_break'><div></div></div><div id="footer">
  <div id="footernav">
    <div class="footernav_left">
      <a href="http://seekingalpha.com" class="footernav_logo"></a>
      <div class="footernav_boards">
          <a href="https://play.google.com/store/apps/details?id=com.seekingalpha.webwrapper" target="_blank" onclick="mobile_app_click()" class="google_play_mini_badge"></a>
          <a href="https://itunes.apple.com/us/app/seeking-alpha-portfolio/id552799694?mt=8" target="_blank" onclick="mobile_app_click()" class="app_store_mini_badge"></a>
      </div>
      <div class="cleaner"></div>
    </div>

     <div class="footernav_share_buttons">
   <a href="https://www.facebook.com/Seekingalpha" class="share_btn fb" sasource="footer" target="_blank"></a>
   <a href="https://twitter.com/SeekingAlpha" class="share_btn twitter" sasource="footer" target="_blank"></a>
   <a href="https://plus.google.com/+SeekingAlphaSA/" class="share_btn google" rel="publisher" sasource="footer" target="_blank"></a>
    </div>
    <div class="footernav_right">
      <div class="footernav_links">
        <a href="http://seekingalpha.com/leader-board/opinion-leaders" sasource="footer">Top Authors</a>&nbsp;&nbsp;|&nbsp;
        <a class="small_rss" href="http://seekingalpha.com/page/feeds" sasource="footer">&nbsp;&nbsp;&nbsp;&nbsp;RSS Feeds</a>&nbsp;&nbsp;|&nbsp;
        <a href="http://seekingalpha.com/sitemap" sasource="footer">Sitemap</a>&nbsp;&nbsp;|&nbsp;
        <a href="http://seekingalpha.com/page/about_us" sasource="footer">About Us</a>&nbsp;&nbsp;|&nbsp;
        <a href="http://seekingalpha.com/page/contact" sasource="footer">Contact Us</a>
      </div>
      <div class="footernav_more_links">
        <a href="http://seekingalpha.com/page/terms-of-use" sasource="footer">Terms of Use</a> |
        <a href="http://seekingalpha.com/page/privacy" sasource="footer">Privacy</a> |
        <a href="http://www.xignite.com" rel="nofollow" target="_blank">Xignite quote data</a> |
        <span>&#169; 2015 Seeking Alpha</span>
      </div>
      <div class="cleaner"></div>
    </div>
  </div>
  <div class="cleaner"></div>
</div>
<script>
  function mobile_app_click(){
    var location_pathname = location.pathname.split('/');
    var source = location.pathname.split('/')[1];

    if (source == '')
      source = 'home_page';
    else if (source == 'account' && location_pathname[2] == 'email_preferences')
      source = 'email_preferences';

    Mone.event('app_promo', 'footer_' + source, 'clicked');
  }
</script>

<div id="first_portfolio_unit_ref" style="display: none"> <div>
  <table id="first_portfolio_unit" style="padding-bottom: 7px !important; padding-top: 4px;">
    <thead><tr><th class="fs12">Symbol</th><th class="tr fs12">Price</th><th class="tr fs12">% Chg</th><th></th><th class="tc fs12">Remove</th><th></th></thead>
    <tbody>
        <tr id="first_portfolio_unit_cell0" class="mb10">
          <td style="width: 25%"><input id="first_portfolio_symbol_input0" class="fpu_input" placeholder="Type Ticker" maxlength="9"></td>
          <td style="width: 22%" id="first_portfolio_unit_symbol_price0" class="tr fs12">-</td>
          <td style="width: 20%" id="first_portfolio_unit_symbol_price_change0" class="tr fs12">-</td>
          <td style="width: 13%">&nbsp;</td>
          <td style="width: 7%" ><span id="first_portfolio_unit_symbol_price_remove_button0" class="remove_btn" onclick="SA.Units.Portfolio.First_portfolio_unit.removeSymbol('first_portfolio_unit_cell0')"></span></td>
          <td style="width: 13%">&nbsp;</td>
        </tr>
        <tr id="first_portfolio_unit_cell1" class="mb10 b-light-gray2">
          <td style="width: 25%"><input id="first_portfolio_symbol_input1" class="fpu_input" placeholder="Type Ticker" maxlength="9"></td>
          <td style="width: 22%" id="first_portfolio_unit_symbol_price1" class="tr fs12">-</td>
          <td style="width: 20%" id="first_portfolio_unit_symbol_price_change1" class="tr fs12">-</td>
          <td style="width: 13%">&nbsp;</td>
          <td style="width: 7%" ><span id="first_portfolio_unit_symbol_price_remove_button1" class="remove_btn" onclick="SA.Units.Portfolio.First_portfolio_unit.removeSymbol('first_portfolio_unit_cell1')"></span></td>
          <td style="width: 13%">&nbsp;</td>
        </tr>
        <tr id="first_portfolio_unit_cell2" class="mb10">
          <td style="width: 25%"><input id="first_portfolio_symbol_input2" class="fpu_input" placeholder="Type Ticker" maxlength="9"></td>
          <td style="width: 22%" id="first_portfolio_unit_symbol_price2" class="tr fs12">-</td>
          <td style="width: 20%" id="first_portfolio_unit_symbol_price_change2" class="tr fs12">-</td>
          <td style="width: 13%">&nbsp;</td>
          <td style="width: 7%" ><span id="first_portfolio_unit_symbol_price_remove_button2" class="remove_btn" onclick="SA.Units.Portfolio.First_portfolio_unit.removeSymbol('first_portfolio_unit_cell2')"></span></td>
          <td style="width: 13%">&nbsp;</td>
        </tr>
        <tr id="first_portfolio_unit_cell3" class="mb10 b-light-gray2">
          <td style="width: 25%"><input id="first_portfolio_symbol_input3" class="fpu_input" placeholder="Type Ticker" maxlength="9"></td>
          <td style="width: 22%" id="first_portfolio_unit_symbol_price3" class="tr fs12">-</td>
          <td style="width: 20%" id="first_portfolio_unit_symbol_price_change3" class="tr fs12">-</td>
          <td style="width: 13%">&nbsp;</td>
          <td style="width: 7%" ><span id="first_portfolio_unit_symbol_price_remove_button3" class="remove_btn" onclick="SA.Units.Portfolio.First_portfolio_unit.removeSymbol('first_portfolio_unit_cell3')"></span></td>
          <td style="width: 13%">&nbsp;</td>
        </tr>
        <tr id="first_portfolio_unit_cell4" class="mb10">
          <td style="width: 25%"><input id="first_portfolio_symbol_input4" class="fpu_input" placeholder="Type Ticker" maxlength="9"></td>
          <td style="width: 22%" id="first_portfolio_unit_symbol_price4" class="tr fs12">-</td>
          <td style="width: 20%" id="first_portfolio_unit_symbol_price_change4" class="tr fs12">-</td>
          <td style="width: 13%">&nbsp;</td>
          <td style="width: 7%" ><span id="first_portfolio_unit_symbol_price_remove_button4" class="remove_btn" onclick="SA.Units.Portfolio.First_portfolio_unit.removeSymbol('first_portfolio_unit_cell4')"></span></td>
          <td style="width: 13%">&nbsp;</td>
        </tr>
        <tr id="first_portfolio_unit_cell5" class="mb10 b-light-gray2">
          <td style="width: 25%"><input id="first_portfolio_symbol_input5" class="fpu_input" placeholder="Type Ticker" maxlength="9"></td>
          <td style="width: 22%" id="first_portfolio_unit_symbol_price5" class="tr fs12">-</td>
          <td style="width: 20%" id="first_portfolio_unit_symbol_price_change5" class="tr fs12">-</td>
          <td style="width: 13%">&nbsp;</td>
          <td style="width: 7%" ><span id="first_portfolio_unit_symbol_price_remove_button5" class="remove_btn" onclick="SA.Units.Portfolio.First_portfolio_unit.removeSymbol('first_portfolio_unit_cell5')"></span></td>
          <td style="width: 13%">&nbsp;</td>
        </tr>
        <tr id="first_portfolio_unit_cell6" class="mb10">
          <td style="width: 25%"><input id="first_portfolio_symbol_input6" class="fpu_input" placeholder="Type Ticker" maxlength="9"></td>
          <td style="width: 22%" id="first_portfolio_unit_symbol_price6" class="tr fs12">-</td>
          <td style="width: 20%" id="first_portfolio_unit_symbol_price_change6" class="tr fs12">-</td>
          <td style="width: 13%">&nbsp;</td>
          <td style="width: 7%" ><span id="first_portfolio_unit_symbol_price_remove_button6" class="remove_btn" onclick="SA.Units.Portfolio.First_portfolio_unit.removeSymbol('first_portfolio_unit_cell6')"></span></td>
          <td style="width: 13%">&nbsp;</td>
        </tr>
        <tr id="first_portfolio_unit_cell7" class="mb10 b-light-gray2">
          <td style="width: 25%"><input id="first_portfolio_symbol_input7" class="fpu_input" placeholder="Type Ticker" maxlength="9"></td>
          <td style="width: 22%" id="first_portfolio_unit_symbol_price7" class="tr fs12">-</td>
          <td style="width: 20%" id="first_portfolio_unit_symbol_price_change7" class="tr fs12">-</td>
          <td style="width: 13%">&nbsp;</td>
          <td style="width: 7%" ><span id="first_portfolio_unit_symbol_price_remove_button7" class="remove_btn" onclick="SA.Units.Portfolio.First_portfolio_unit.removeSymbol('first_portfolio_unit_cell7')"></span></td>
          <td style="width: 13%">&nbsp;</td>
        </tr>
    </tbody>
  </table>
</div>

<script>SA.Units.Portfolio.First_portfolio_unit.init('first_portfolio_symbol_input',8, 'transcript Register')</script>
</div>

<script type="text/javascript">
  Event.observe(window, 'scroll', run_article_end_mone);
  SA.Utils.Sharing.setSharingButtons('Article',ARTICLE_ID);

  if (location.href.match(/part=single/) == null){
    setRoadblockMandatoryTickers();
  	$('tab_cmd').show();
  	$('pag_cmd').show();
  }


  $('last_page_index').innerHTML = getPartialSlice(1,sliceSize,false,true,true);


  /* Roadblock test */
  function transcript_rb_show(){
    if (readCookie('user_email') && readCookie('user_email').length > 0 && !AlphaBox.isOpen) {
      SA.Utils.Popup.roadblock_login();
      createCookie('singlepageafterlogin',true);
      return;
    }

   //temporary remove iPad promo
   /*if (SA.Utils.Env.isIPad){
       ipad_roadblock_new();
   }*/
    else {
      if (document.viewport.getDimensions().height > 400){
        title = "Seeking Alpha transcribes 10,000+ earnings calls per year. For full, free access to these transcripts, please register and set up a portfolio in two easy steps:";
        createCookie('singlepageafterlogin',true);
        new RoadblockPopup('roadblock', 'transcript_register').roadblock_transcripts();
      }
    }
  }
  /* Roadblock test */
  function singlePageView(){
    if (SA.Data.User.loggedIn() || SA.Pages.Article.fromInsightCenters()) {
      transcriptRedirect("single");
    } else {
      transcript_rb_show();
    }
  }

  SeekingAlpha.Initializer.onDOMLoad(function(){

    /* Roadblock test */

    SA.Pages.Article.primary = "aker";
    SA.Pages.Article.init();

    rb = new roadblock('transcript');
    rb.additional_login_title = " for full transcript access";
    rb.register_show = transcript_rb_show;
    if (!readCookie("sessioncfr") && !SA.Pages.Article.skipFirstArticleRoadblock()) {
      if (!SA.Data.User.loggedIn() && !SA.Pages.Article.from_partner() && !SA.Pages.Article.fromEarningsCenter() && document.viewport.getDimensions().height > 400) {
        var firstPageTestValue = SA.Pages.Article.RoadblockTimeInFirstPageTest();
        if (location.href.match("page=([0-9]+)") && location.href.match("page=([0-9]+)")[1] > 1) {
          new RoadblockPopup('roadblock', 'transcript_register').roadblock_transcripts();
        } else if (firstPageTestValue) {
          setTimeout(function(){ new RoadblockPopup('roadblock', 'transcript_register').roadblock_transcripts(); }, firstPageTestValue * 1000);
        }
      }
    }
    if (!SA.Data.User.loggedIn() &&!SA.Pages.Article.fromInsightCenters()){
      SA.Pages.Article.hide_features_for_roadblock();
      if($('bottom_rta_unit')) {$('bottom_rta_unit').style.display = 'none';}
      if ($('tab_single_bottom')) {$('tab_single_bottom').show();}
    }
    /* Roadblock test */
  });

    SeekingAlpha.Initializer.AddAfterLoad(function(){
      SA.Pages.Article.articlePromo({"allSlugs":["aker"],"primarySlug":"aker"});
    });
</script>
    

<link href="//staticseekingalpha3.a.ssl.fastly.net/stylesheets/packaged/footer_packaged.css?h=1vogfdq.css" media="screen" rel="stylesheet" type="text/css" /><script type="text/javascript">
    window.jspell_urls = ["//staticseekingalpha3.a.ssl.fastly.net/javascripts/packaged/jspell_packaged.js?h=6a842a.js"]
    if(typeof (authors) == "undefined" || typeof (symbols) == "undefined")
        load_remote_script("//staticseekingalpha.a.ssl.fastly.net/javascripts/packaged/sa.js");
    if(is_users_cookie_exists() && !cookieExists('tops') && typeof(tops) == "undefined")
        load_remote_script("//staticseekingalpha1.a.ssl.fastly.net/javascripts/tops.js?h=uayop.js");
    Mone.renderedParams = {};
    SeekingAlpha.Initializer.AddAfterLoad(function(){SA.Performance.Utils.loadPrintStyle('//staticseekingalpha1.a.ssl.fastly.net/stylesheets/print.css?t=1439927534')});

    function switch_status(){
        new Ajax.Request('/authentication/get_menu', {
            asynchronous:true,
            method:'get',
            onComplete: function(transport) {
                eval(transport.responseJSON.code);
            }
        });
    }
    PortfolioNotification.run();
</script>

<noscript>
  <img src="http://b.scorecardresearch.com/p?c1=2&c2=8500672&cv=2.0&cj=1" width="0" height="0" />
</noscript>

<script type="text/javascript" src="//staticseekingalpha.a.ssl.fastly.net/pages/ads_399990.js"></script>

    <script crossorigin="use-credentials" src="//staticseekingalpha1.a.ssl.fastly.net/javascripts/packaged/footer_packaged.js?h=iyjmiy.js" type="text/javascript"></script>

<script type="application/ld+json">
    {
      "@context": "http://schema.org",
      "@type": "Organization",
      "name": "Seeking Alpha",
      "url": "http://seekingalpha.com",
      "logo": "//staticseekingalpha3.a.ssl.fastly.net/assets/social-50f1e86b5c7a0fda6a96bf2280e5360d.png",
      "sameAs" : [
        "https://plus.google.com/+SeekingAlphaSA",
        "https://twitter.com/SeekingAlpha",
        "https://www.facebook.com/Seekingalpha",
        "https://en.wikipedia.org/wiki/Seeking_Alpha",
        "https://www.linkedin.com/company/seeking-alpha"
      ]
    }
</script>
<script type="application/ld+json">
    {
       "@context": "http://schema.org",
       "@type": "WebSite",
       "url": "http://seekingalpha.com",
       "potentialAction": {
         "@type": "SearchAction",
         "target": "http://seekingalpha.com/search/?q={search_term_string}",
         "query-input": "required name=search_term_string"
       }
    }
</script>
<div id="symbol_data_script_container"></div>
<script type="text/javascript">
SeekingAlpha.Initializer.onDOMLoad(function(){
  if(SA.Pages && SA.Pages.Account && SA.Pages.Account.Portfolios){
    var a = SA.Pages.Account.Portfolios.alertsTab;
    SA.Pages.Account.Portfolios.alertsTab = function(b){if ($('ziignight_submit')) a(b);}
  }
});
if (/\/account\/portfolio/.test(location.href)) {document.getElementsByTagName("html")[0].style.overflow = "auto"};
if (!$("comment_form_wrapper") && /seekingalpha\.com\/currents\/post/.test(location.href) && $("ads_and_tools")){ $("ads_and_tools").style.position = 'absolute';$("ads_and_tools").style.top="60px";$("ads_and_tools").style.right="0";};
</script>
<style>
.portfolio_news #content_wrapper .left_content .market_currents ul#mc_news li  .bullet{* position: static;* padding:0 6px 6px 1px;}
</style>
<script>
if (/article\/2953766/.test(location.href) && $('etf_hub_promo')) setTimeout(function(){ $('etf_hub_promo').style.display = 'none'},150);
</script>


    <div class="cleaner"></div>
  </body>
</html>
